Venus Concept Inc (VERO)

$0.568

+0.04

(+7.17%)▲

Market is closed - opens 7 PM, 04 Jun 2024

Insights on Venus Concept Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 17.61M → 18.13M (in $), with an average increase of 2.9% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -7.40M → -11.11M (in $), with an average decrease of 22.5% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 45.7% return, outperforming this stock by 119.0%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 79.6% return, outperforming this stock by 177.9%

Performance

  • $0.52
    $0.57
    $0.57
    downward going graph

    8.49%

    Downside

    Day's Volatility :8.49%

    Upside

    0.0%

    downward going graph
  • $0.46
    $2.60
    $0.57
    downward going graph

    19.25%

    Downside

    52 Weeks Volatility :82.3%

    Upside

    78.08%

    downward going graph

Returns

PeriodVenus Concept IncIndex (Russel 2000)
3 Months
-31.73%
0.0%
6 Months
-61.08%
0.0%
1 Year
-72.95%
0.0%
3 Years
-98.34%
-22.6%

Highlights

Market Capitalization
3.4M
Book Value
- $3.54
Earnings Per Share (EPS)
-6.92
Wall Street Target Price
10.6
Profit Margin
-51.0%
Operating Margin TTM
-44.4%
Return On Assets TTM
-17.63%
Return On Equity TTM
-463.54%
Revenue TTM
73.3M
Revenue Per Share TTM
13.11
Quarterly Revenue Growth YOY
-14.899999999999999%
Gross Profit TTM
74.1M
EBITDA
-23.8M
Diluted Eps TTM
-6.92
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-5.4
EPS Estimate Next Year
-1.58
EPS Estimate Current Quarter
-1.53
EPS Estimate Next Quarter
-1.3

Analyst Recommendation

Hold
    0
    0%Buy
    62%Hold
    37%Sell
Based on 8 Wall street analysts offering stock ratings for Venus Concept Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
5
5
5
Sell
3
3
3

Analyst Forecast

What analysts predicted

Upside of 1766.2%

Current $0.57
Target $10.60

Company Financials

FY18Y/Y Change
Revenue
22.0M
↑ 3.09%
Net Income
-28.7M
↑ 61.0%
Net Profit Margin
-130.83%
↓ 47.05%
FY19Y/Y Change
Revenue
110.4M
↑ 402.85%
Net Income
-42.3M
↑ 47.24%
Net Profit Margin
-38.31%
↑ 92.52%
FY20Y/Y Change
Revenue
78.0M
↓ 29.34%
Net Income
-82.8M
↑ 95.81%
Net Profit Margin
-106.16%
↓ 67.85%
FY21Y/Y Change
Revenue
105.6M
↑ 35.39%
Net Income
-22.1M
↓ 73.27%
Net Profit Margin
-20.96%
↑ 85.2%
FY22Y/Y Change
Revenue
99.5M
↓ 5.8%
Net Income
-43.6M
↑ 96.85%
Net Profit Margin
-43.8%
↓ 22.84%
FY23Y/Y Change
Revenue
76.4M
↓ 23.26%
Net Income
-37.3M
↓ 14.53%
Net Profit Margin
-48.79%
↓ 4.99%
Q3 FY22Q/Q Change
Revenue
21.5M
↓ 21.0%
Net Income
-14.5M
↑ 37.9%
Net Profit Margin
-67.3%
↓ 28.75%
Q4 FY22Q/Q Change
Revenue
24.3M
↑ 12.75%
Net Income
-9.9M
↓ 31.43%
Net Profit Margin
-40.93%
↑ 26.37%
Q1 FY23Q/Q Change
Revenue
20.5M
↓ 15.46%
Net Income
-9.6M
↓ 3.19%
Net Profit Margin
-46.87%
↓ 5.94%
Q2 FY23Q/Q Change
Revenue
20.1M
↓ 2.22%
Net Income
-7.4M
↓ 23.01%
Net Profit Margin
-36.91%
↑ 9.96%
Q3 FY23Q/Q Change
Revenue
17.6M
↓ 12.25%
Net Income
-9.1M
↑ 22.39%
Net Profit Margin
-51.48%
↓ 14.57%
Q1 FY24Q/Q Change
Revenue
18.1M
↑ 2.93%
Net Income
-11.1M
↑ 22.58%
Net Profit Margin
-61.31%
↓ 9.83%
FY18Y/Y Change
Total Assets
31.0M
↓ 6.06%
Total Liabilities
29.4M
↑ 48.62%
FY19Y/Y Change
Total Assets
191.1M
↑ 517.08%
Total Liabilities
114.4M
↑ 289.4%
FY20Y/Y Change
Total Assets
160.5M
↓ 16.01%
Total Liabilities
116.8M
↑ 2.02%
FY21Y/Y Change
Total Assets
153.9M
↓ 4.15%
Total Liabilities
112.3M
↓ 3.85%
FY22Y/Y Change
Total Assets
125.4M
↓ 18.52%
Total Liabilities
116.6M
↑ 3.89%
FY23Y/Y Change
Total Assets
93.7M
↓ 25.3%
Total Liabilities
107.1M
↓ 8.18%
Q3 FY22Q/Q Change
Total Assets
120.6M
↓ 9.13%
Total Liabilities
110.6M
↑ 1.15%
Q4 FY22Q/Q Change
Total Assets
125.4M
↑ 3.94%
Total Liabilities
116.6M
↑ 5.45%
Q1 FY23Q/Q Change
Total Assets
112.8M
↓ 10.02%
Total Liabilities
113.0M
↓ 3.11%
Q2 FY23Q/Q Change
Total Assets
106.2M
↓ 5.9%
Total Liabilities
111.7M
↓ 1.17%
Q3 FY23Q/Q Change
Total Assets
98.9M
↓ 6.82%
Total Liabilities
110.3M
↓ 1.25%
Q1 FY24Q/Q Change
Total Assets
93.7M
↓ 5.32%
Total Liabilities
107.1M
↓ 2.9%
FY18Y/Y Change
Operating Cash Flow
-28.7M
↑ 49.04%
Investing Cash Flow
-8.7M
↑ 466.93%
Financing Cash Flow
22.2M
↓ 24.28%
FY19Y/Y Change
Operating Cash Flow
-39.6M
↑ 37.97%
Investing Cash Flow
6.4M
↓ 173.74%
Financing Cash Flow
42.2M
↑ 89.79%
FY20Y/Y Change
Operating Cash Flow
-28.7M
↓ 27.64%
Investing Cash Flow
-2.4M
↓ 137.47%
Financing Cash Flow
49.7M
↑ 17.7%
FY21Y/Y Change
Operating Cash Flow
-19.8M
↓ 30.99%
Investing Cash Flow
-552.0K
↓ 76.92%
Financing Cash Flow
16.8M
↓ 66.14%
Q3 FY22Q/Q Change
Operating Cash Flow
-3.9M
↓ 47.04%
Investing Cash Flow
-46.0K
↓ 51.06%
Financing Cash Flow
143.0K
↑ 1091.67%
Q4 FY22Q/Q Change
Operating Cash Flow
-3.4M
↓ 11.74%
Investing Cash Flow
-22.0K
↓ 52.17%
Financing Cash Flow
8.2M
↑ 5660.84%
Q1 FY23Q/Q Change
Operating Cash Flow
-5.9M
↑ 72.82%
Investing Cash Flow
-22.0K
↑ 0.0%
Financing Cash Flow
803.0K
↓ 90.25%
Q2 FY23Q/Q Change
Operating Cash Flow
-2.1M
↓ 63.96%
Investing Cash Flow
-22.0K
↑ 0.0%
Financing Cash Flow
1.9M
↑ 130.64%

Technicals Summary

Sell

Neutral

Buy

Venus Concept Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Venus Concept Inc
Venus Concept Inc
-14.87%
-61.08%
-72.95%
-98.34%
-99.27%
Stryker Corporation
Stryker Corporation
4.27%
16.65%
22.1%
34.77%
82.03%
Boston Scientific Corp.
Boston Scientific Corp.
4.07%
37.85%
46.89%
79.63%
93.34%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
3.26%
27.0%
2.23%
-8.36%
51.45%
Abbott Laboratories
Abbott Laboratories
-2.62%
-2.21%
-0.86%
-5.87%
32.8%
Medtronic Plc
Medtronic Plc
0.44%
2.96%
-1.92%
-33.69%
-13.02%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Venus Concept Inc
Venus Concept Inc
NA
NA
NA
-5.4
-4.64
-0.18
NA
-3.54
Stryker Corporation
Stryker Corporation
38.89
38.89
2.92
11.96
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
63.5
63.5
1.8
2.33
0.09
0.05
NA
13.56
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
37.45
37.45
5.19
2.76
0.21
0.12
NA
11.82
Abbott Laboratories
Abbott Laboratories
31.83
31.83
5.99
4.63
0.15
0.06
0.02
22.31
Medtronic Plc
Medtronic Plc
29.48
29.48
1.52
5.2
0.07
0.04
0.03
38.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Venus Concept Inc
Venus Concept Inc
Hold
$3.4M
-99.27%
NA
-51.0%
Stryker Corporation
Stryker Corporation
Buy
$129.9B
82.03%
38.89
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$111.1B
93.34%
63.5
12.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$52.4B
51.45%
37.45
23.01%
Abbott Laboratories
Abbott Laboratories
Buy
$177.8B
32.8%
31.83
13.96%
Medtronic Plc
Medtronic Plc
Buy
$106.7B
-13.02%
29.48
11.36%

Institutional Holdings

  • Essex Woodlands Health Ventures

    17.14%

  • Masters Capital Management LLC

    5.25%

  • TWO SIGMA SECURITIES, LLC

    0.58%

  • Vanguard Group Inc

    0.51%

  • Geode Capital Management, LLC

    0.33%

  • Tower Research Capital LLC

    0.08%

Company Information

venus concept is a leader in the global medical aesthetic market, pairing best-in-class technology with the first and only true subscription model in the industry. our goal is to help both new and established practices succeed in this growing field. we understand the challenges of breaking into and being successful in the aesthetics industry, and that’s why we’re changing the game with an innovative solution. the secret is in our industry-unique subscription model. in partnering with venus concept, aesthetic professionals worldwide gain access to never-before-seen business features such as the most comprehensive warranty program, unmatched marketing support, continuous clinical education, valuable practice enhancement programs, and more. together with this business model, our collection of aesthetic systems—including venus versa™, venus legacy™, venus velocity™, venus viva™, venus freeze plus™, and venus skin™—are setting higher industry standards and improving the quality of life for

Organization
Venus Concept Inc
Employees
304
CEO
Dr. Hemanth Jacob Varghese CFA, Ph.D.
Industry
Health Technology

Discover More

FAQs